leisure time -WSS

leisure time

author：fashion 2025-10-03 00:03:53 - browse：97

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

WSS

Pancreatic cancer early detection could be helped by AI

Merck, Johnson & Johnson CEOs will testify on high drug prices

5 takeaways from STAT's examination of Zynex Medical

Pancreatic cancer early detection could be helped by AI

How faith leaders like me can help address America's obesity epidemic

Investment in vaccine development is lagging, report finds

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Teladoc has a new CEO, but challenges remain the same

Heart attack and stroke risk calculators need revising

10 reasons why health care startups fail

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

New report analyzes digital physical therapy solutions' effectiveness

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

focus

Readers discuss the intersection of pregnancy and addiction

Coercive sterilizations revealed by STAT prompt outrage

Philips to halt sales of sleep apnea machines in U.S.

The Affordable Care Act has saved billions in health care costs

Investment in vaccine development is lagging, report finds

Why Medicare shouldn’t cover every FDA

focus

focus

Wikipedia

hotspot